TATaner Akyol

Taner Akyol

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Taner Akyol has a total of 361 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gastroenteroloji Textbook - Cilt (1-2)

    by Alper Macif, Ahmed Ramiz Baykan, Gökhan Çoban, Sadık Yavuz, Berk Bas, Mehmet Kasım Aydın, Selçuk Candan, Fatih Güzelbulut, Atilla Bulur, Fatih Ensaroğlu, et al.

  • Open Access

    Özofagus Malign Tümörleri

    by Taner Akyol, Umut Emre Aykut

    Özofagus kanserleri dünya genelinde en sık görülen sekizinci kanserlerdir. Skuamöz hücreli karsinom ile adenokarsinom olarak iki alt grubu bulunmaktadır. Geç semptom verdiğinden lokal ileri evrede karşımıza çıkmaktadırlar. Tanı ve evreleme aşamasında çeşitli görüntüleme yöntemlerinden (BT/MRI/EUS/PET-CT) yararlanmaktayız. Tedavide, submukozayı geçmeyen tümörlerde endoskopik tedaviler önerilirken, daha ileri evreler için cerrahi ve kemoradyoterapi uygulanmaktadır.

  • Open Access

    Outcomes of liver transplantation patients infected with COVID-19: pandemic hospital experience from Turkey

    by Taner Akyol, Tolga Düzenli̇

    Aims: There are conflicting results for the course of the disease and mortality rates for liver transplantation patients infected with COVID-19. In this study, we aimed to present the outcomes of our liver transplant patients who were hospitalized and followed up in our tertiary hospital, which served as a pandemic hospital for COVID-19. Methods: Patients hospitalized with the diagnosis of COVID-19 between March 1, 2020 and March 1, 2022 in Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital and Prof. Dr. Feriha Öz Pandemic Hospital were included. In this retrospective observational study, the clinical data of the patients, the need for intensive care hospitalization, and mortality rates were recorded by hospital computer system. The relationships were analyzed with SPSS v20.0. Results: There were 25996 patients who were hospitalized with the diagnosis of COVID-19 and 28 of them were with the history of liver transplantation. Ages of the liver transplant patients ranged from 18 to 73, with a median age of 52. 82.1% of the patients were male and 17.9% were female. Intensive care unit hospitalization rate was 25% and mortality rate was 14.3%. The relationships according to the age groups revealed that all of the women were under the age of 50 (p=0.008) and the patients who deceased were male patients over the age of 50 (p=0.044). Conclusion: Mortality rates and intensive care unit requirements of chronically immunosuppressed liver transplant patients with COVID-19 infection were similar with general population. Complete immunosuppression withdrawal should not be urged in this population.

  • Open Access

    Mide prekanseröz lezyonlarında klopidogrel kullanımının değerlendirilmesi: Kemopreventif etkisi var mı?

    by Taner Akyol

    Aims: Gastric malignancies are the third most common cause of cancer-related deaths. Although aspirin and clopidogrel have been reported to reduce the risk of colorectal cancer, their effects on gastric cancer are still under investigation. In this study, we aimed to determine whether clopidogrel has an effect on the development of gastric precancerous lesions. Methods: The study was designed as a retrospective case-control study. The study was conducted between January 2021 and April 2023 in the Gastroenterology Clinic of Samsun University Samsun Training and Research Hospital. Patients who underwent upper GIS endoscopy and biopsy examination due to dyspeptic complaints were scanned from the electronic data system of the hospital and their data were recorded by forming 4 groups as clopidogrel (89 patients), low-dose aspirin (ASA) (172 patients), non-aspirin non-steroidal anti-inflammatory drug (NA-NSAID) users (110 patients) and control group without antiplatelet use (110 patients). Statistical analyses were accomplished with SPSS for Windows v20.0. Results: Mean duration of drug use was 2 years for clopidogrel, 1.47 years for ASA and 0.35 years for NA-NSAID. The incidence of peptic ulcer was 7.2% in the control group, 38%, 15.1%, 49% in clopidogrel, ASA, NA-NSAID users, respectively (p<0.001). The frequency of H. pylori infection in the groups was 61%, 53.5%, 40.1%, 46.1%, respectively. There was a significant difference between ASA and control group (p<0.001). Intestinal metaplasia was observed in 23.1%, 29.5%, 31.2%, 23.1%, respectively (p=0.291). Atrophic gastritis was 16.6%, 35.2%, 19.2%, 29.3%, respectively (p=0.003). No difference was observed between the groups in terms of dysplasia, gastric cancer and esophageal cancer. Conclusion: According to our results, no preventive effects of clopidogrel, ASA and NA-NSAID use on precancerous lesions or gastric cancer development were observed. However, the use of these drugs was associated with severe gastroduodenal lesions. Amaç: Mide maligniteleri kansere bağlı ölümlerin en sık üçüncü nedenidir. Aspirin ve klopidogrelin kolorektal kanser riskini azalttığı bildirilse de mide kanseri üzerindeki etkileri halen araştırılmaktadır. Bu çalışmanın amacı; klopidogrelin gastrik prekanseröz lezyonların gelişiminde etkisinin olup olmadığını belirlemektir. Gereç ve Yöntemler: Çalışma retrospektif vaka kontrol çalışması olarak tasarlandı. Çalışma Ocak 2021-Nisan 2023 tarihleri arasında Samsun Üniversitesi Samsun Eğitim ve Araştırma Hastanesi Gastroenteroloji Kliniğinde gerçekleştirildi. Dispepsi şikayeti nedeniyle üst GİS endoskopisi ve biyopsi incelemesi yapılan hastalar hastanenin elektronik veri sisteminden taranarak klopidogrel (89 hasta), düşük doz aspirin (ASA) (172 hasta), aspirin dışı non-steroid antiinflamatuar ilaç (NA-NSAID) (110 hasta) kullanıcıları ve antiplatelet kullanmayan kontrol grubu (110 hasta) olmak üzere 4 grup oluşturularak verileri kaydedildi. İstatistiksel analizler SPSS v20.0 ile yapıldı. Bulgular: Ortalama ilaç kullanım süresi klopidogrel için 2 yıl, ASA için 1,47 yıl ve NA-NSAID için 0,35 yıl idi. Peptik ülser görülme sıklığı kontrol grubunda %7,2, klopidogrel, ASA, NA-NSAİİ kullananlarda sırasıyla %38, %15,1, %49 idi (p<0,001). Gruplarda H. pylori enfeksiyonu sıklığı sırasıyla %61, %53,5, %40,1, %46,1 idi. ASA ile kontrol grubu arasında anlamlı fark vardı (p<0,001). Bağırsak metaplazisi sırasıyla %23,1, %29,5, %31,2, %23,1 oranında görüldü (p=0,291). Atrofik gastrit oranları sırasıyla %16,6, %35,2, %19,2, %29,3 idi (p=0,003). Displazi, mide kanseri ve yemek borusu kanseri açısından gruplar arasında fark gözlenmedi. Sonuç: Sonuçlarımıza göre klopidogrel, ASA ve NA-NSAID kullanımının prekanseröz lezyonları veya mide kanseri gelişimini önleyici etkisi gözlenmedi. Ancak bu ilaçların kullanımı ciddi gastroduodenal lezyonlarla ilişkilendirilmiştir.

  • Open Access

    In the Diagnosis of Liver Fibrosis Developing in Nonalcoholic Fatty Liver Patients; Could Serum Fetuin A Be a Candidate Biomarker

    by Taner Akyol

    Previous studies have reported in the literature that fetuin A, released from the liver, may be a useful serum biomarker in the diagnosis of nonalcoholic fatty liver disease (NAFLD). However, results are not consistent in predicting nonalcoholic steatohepatitis (NASH) and fibrosis, which are indicative of progressive NAFLD patients. The aim of this study was to investigate the importance of serum fetuin A in detecting NASH and fibrosis, which are determinants of morbidity, in patients with liver biopsy-proven NAFLD. This observational case-control study included 40 NAFLD patients diagnosed by liver biopsy and 25 healthy volunteer controls. The demographic characteristics of the patients and healthy volunteers were recorded, biochemical tests were done, and the serum fetuin A levels of the participants were determined by the enzyme-linked immunosorbent assay method. Serum fetuin A levels were significantly higher in both the nonalcoholic fatty liver (NAFL) (608.30 μg/mL; p<0.001) and NAFLD (536.58 μg/mL; p=0.008) groups compared to the control group (345.07 μg/mL). However, no significant difference was detected in the NASH group (417.06 μg/mL; p=0.740). When patients with and without fibrosis were compared, the mean serum fetuin A levels of patients with fibrosis were significantly lower (708 μg/mL and 380 μg/mL, respectively; p<0.001). When receiver operating characteristic (ROC) analysis was performed, the best cut-off point for patients with fibrosis was 510.98 μg/mL with 94.7% sensitivity and 66.7% specificity (p<0.001). Serum fetuin A may be a useful biomarker in the diagnosis of NAFLD patients and in predicting liver fibrosis.

  • Prevalence of Rotavirus, Adenovirus, and Hepatitis A Virus in a Tertiary Care Hospital in Somalia

    by Marian Muse Osman, Faduma Nur Adan, Taner Akyol, Hilmi Erdem Sümbül

    Rotavirus, one of the viral infectious agents that is transmitted mainly through the fecal-oral route and spreads easily in regions with poor sanitation conditions, is the most common causative agent of acute gastroenteritis in children under five years of age worldwide, and enteric adenoviruses are other frequently encountered causative agents of gastroenteritis in childhood. Hepatitis A virus (HAV) is also transmitted in similar routes and is endemic in regions with poor sanitation conditions and limited access to clean water and is usually acquired in early childhood in these regions. In this study conducted in Mogadishu Somalia, rotavirus and adenovirus antigen test (immunochromatographic rapid test) results in patients admitted to a tertiary hospital in the 9-month period between February 2019 and October 2019 and ELISA based HAV antibody test results studied in 2018-2019 were retrospectively examined and it was aimed to determine the distribution of positivity rates of these viruses by age, gender, and year. During the study period, 1136 patients (mean age 6.33±12.36) were tested for rotavirus and adenovirus antigens, and 362 patients (mean age 21.26±18.45) were tested for anti-HAV IgM/IgG antibodies. The positivity rates of rotavirus and adenovirus were found as 17.8% and 5.1%, respectively. The positivity rates of anti-HAV IgM and IgG antibodies were 26.5% and 85.4%. The age group with the highest rotavirus test positivity was babies under one year old (27.3%), positivity rate was also high in children aged 1-2 years old (20.9%), and this distribution was similar for adenovirus. Although a small number of patients were tested in under five years of age, anti-HAV IgG seropositivity was 60% and above in all age groups. The highest anti-HAV IgM positivity rates were observed in children 2-<5 and 5-15 years of age, 52.9% and 44% respectively. Rotavirus antigen positivity was found at high levels in the three-month period covering June, July, and August 2019. In July (2019), it was observed that the number of rotavirus and adenovirus antigen test requests were increased, and also, at the same time the highest positivity rates for both viruses were observed; 31.2% and 9.5% for rotavirus and adenovirus. Rotavirus and enteric adenovirus co-infection was detected in 2.4% (27/1136) of the patients, and 23 (85.2%) of these were under five years of age children. Our study results show that children under the age of two are especially affected by rotavirus and adenovirus infections in Somalia and indicate that HAV infections are acquired at an early childhood. We can say that it may be useful to review vaccination programs as an important public health measure to reduce the burden of mortality and morbidity associated with HAV and rotavirus, which have a high prevalence and also have protective vaccines.


  • Open Access

    Impact of selective serotonin receptor inhibitors on gastric histopathology in patients with depression

    by Taner Akyol, Ali Muhtaroğlu, Demet Şeker, Ahmet Cumhur Dülger

    Objective: Antidepressant medications such as Selective Serotonin Reuptake Inhibitors (SSRI) and Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) are used in the psychopharmacological treatment for various types conditions. This study aimed to investigate whether SSRIs and SNRIs could reduce gastric intestinal metaplasia. Material Methods: A total of 212 patients who underwent upper gastrointestinal endoscopy plus biopsy in our clinic and were using selective serotonin reuptake inhibitors and other potent serotonin reuptake inhibitors were included in the study. A control group was created with a total of 230 age and gender matched patients who underwent upper gastrointestinal endoscopy plus biopsy but had no SSRI or SNRI usage. Patients’ endoscopic and pathologic findings were recorded retrospectively and compared between the groups. Results: The patient group consisted of 180 (84.9%) male and 32 (15.1%) female patients, while the control group included 175 (76.1%) male and 55 (23.29%) female patients. There was a statistically significant difference between the groups in terms of gender (p=0.020). The rates of erythematous antral gastritis (pConclusion: SSRIs/SNRIs may potentially be used in treating gastrointestinal inflammation and metaplasia. However, further prospective randomised studies with larger series are needed to support our findings.

  • Open Access

    Evaluation of serum CXC chemokine ligand 16 (CXCL16) as a novel inflammatory bio- marker or familial Mediterranean fever disease

    by Taner Akyol, Tolga Düzenli̇, Alpaslan Tanoğlu

    FMF is a disease that is mainly diagnosed with clinical features. Several well-known inflammatory markers increase in FMF. However, there is still a need for diagnostic tests for specifying FMF and monitoring inflammatory activity. CXCL16 is a chemokine produced by inflammatory cells that demonstrate efficacy in the acute phase response. In this study, we aimed to investigate the relationship between CXCL16 levels and FMF disease and to evaluate CXCL16 levels as a novel biomarker for FMF. Fifty-three male patients diagnosed with FMF and sixty healthy individuals were included in this cross-sectional study. Blood samples were taken in the first 24 hours of the attack periods. Serum soluble CXCL16 was evaluated by ELISA method. CXCL16 (p<0.001), erythrocyte sedimentation rate (p<0.001), C-reactive protein (p<0.001) and fibrinogen (p=0.005) were significantly higher in FMF group than in control group. Receiver operating characteristic (ROC) curve analysis revealed a cut off value of CXCL16 as 2.68 ng/ml with 83% sensitivity and 68% specificity (p<0.001). Logistic regression analysis indicated that high CXCL16 and erythrocyte sedimentation rate levels were predictive parameters for FMF disease (OR 8.31; 95% CI 2.59-26.62; p <0.001) (OR 1.27; 95% CI 1.12-1.44; p<0.001). There was no correlation between CXCL16 levels and attack frequency and disease duration (p=0.395, p=0.956). To the best of our knowledge, this is the first study evaluating serum soluble CXCL16 levels as a biomarker for FMF. CXCL16 levels were significantly higher and were predictive for monitoring inflammatory activity in patients with FMF. CXCL16 may be a promising biomarker for FMF diagnosis.